147 related articles for article (PubMed ID: 37944569)
1. Platinum-based chemotherapy induces demyelination of Schwann cells in oral squamous cell carcinoma treatment.
Wang X; Yang W; Wang L; Zheng L; Choi WS
Toxicol Appl Pharmacol; 2023 Dec; 481():116751. PubMed ID: 37944569
[TBL] [Abstract][Full Text] [Related]
2. Role of the DNA base excision repair protein, APE1 in cisplatin, oxaliplatin, or carboplatin induced sensory neuropathy.
Kelley MR; Jiang Y; Guo C; Reed A; Meng H; Vasko MR
PLoS One; 2014; 9(9):e106485. PubMed ID: 25188410
[TBL] [Abstract][Full Text] [Related]
3. Taxanes and platinum derivatives impair Schwann cells via distinct mechanisms.
Imai S; Koyanagi M; Azimi Z; Nakazato Y; Matsumoto M; Ogihara T; Yonezawa A; Omura T; Nakagawa S; Wakatsuki S; Araki T; Kaneko S; Nakagawa T; Matsubara K
Sci Rep; 2017 Jul; 7(1):5947. PubMed ID: 28729624
[TBL] [Abstract][Full Text] [Related]
4. Cellular pharmacokinetic/pharmacodynamic relationship of platinum cytostatics in head and neck squamous cell carcinoma evaluated by liquid chromatography coupled to tandem mass spectrometry.
Theile D; Detering JC; Herold-Mende C; Dyckhoff G; Haefeli WE; Weiss J; Burhenne J
J Pharmacol Exp Ther; 2012 Apr; 341(1):51-8. PubMed ID: 22207655
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer.
Park SJ; Ye W; Xiao R; Silvin C; Padget M; Hodge JW; Van Waes C; Schmitt NC
Oral Oncol; 2019 Aug; 95():127-135. PubMed ID: 31345380
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724).
Albany C; Dockter T; Wolfe E; Le-Rademacher J; Wagner-Johnston N; Einhorn L; Lafky JM; Smith E; Pachman D; Staff N; Ma C; Loprinzi CL; Costello BA
Support Care Cancer; 2021 Feb; 29(2):833-840. PubMed ID: 32500206
[TBL] [Abstract][Full Text] [Related]
7. In squamous cell head and neck cancer: which platinum, how much and how often?
Nwizu T; Adelstein DJ
Expert Rev Anticancer Ther; 2014 Sep; 14(9):1033-9. PubMed ID: 24998393
[TBL] [Abstract][Full Text] [Related]
8. The expression of copper transporters associated with the ototoxicity induced by platinum-based chemotherapeutic agents.
Perde-Schrepler M; Fischer-Fodor E; Virag P; Brie I; Cenariu M; Pop C; Valcan A; Gurzau E; Maniu A
Hear Res; 2020 Mar; 388():107893. PubMed ID: 32006874
[TBL] [Abstract][Full Text] [Related]
9. PARP inhibition in platinum-based chemotherapy: Chemopotentiation and neuroprotection.
McQuade RM; Stojanovska V; Bornstein JC; Nurgali K
Pharmacol Res; 2018 Nov; 137():104-113. PubMed ID: 30278221
[TBL] [Abstract][Full Text] [Related]
10. Toxicity of platinum compounds.
Hartmann JT; Lipp HP
Expert Opin Pharmacother; 2003 Jun; 4(6):889-901. PubMed ID: 12783586
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of platinum-drug cytotoxicity in a human head and neck squamous cell carcinoma line and its platinum-resistant variant by liposomal amphotericin B and phospholipase A2-II.
Ferguson PJ; Currie C; Vincent MD
Drug Metab Dispos; 1999 Dec; 27(12):1399-405. PubMed ID: 10570020
[TBL] [Abstract][Full Text] [Related]
12. Multicenter prospective phase II trial of concurrent chemoradiotherapy with weekly low-dose carboplatin for cisplatin-ineligible patients with advanced head and neck squamous cell carcinoma.
Ueki Y; Ohshima S; Yokoyama Y; Takahashi T; Shodo R; Yamazaki K; Ohtaki K; Saijo K; Tanaka R; Togashi T; Sato Y; Takano S; Omata J; Takahashi N; Okabe R; Horii A
Int J Clin Oncol; 2024 Jan; 29(1):20-26. PubMed ID: 37843751
[TBL] [Abstract][Full Text] [Related]
13. [Combined radiotherapy with cis- or carboplatin in advanced head and neck tumors].
Zamboglou N; Pape H; Schnabel T; Wurm R; Bannach B; Fürst G; Schmitt G
Strahlenther Onkol; 1989 Sep; 165(9):647-51. PubMed ID: 2678546
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of concurrent carboplatin plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.
Hamauchi S; Yokota T; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H
Jpn J Clin Oncol; 2015 Dec; 45(12):1116-21. PubMed ID: 26423341
[TBL] [Abstract][Full Text] [Related]
15. Cilostazol is an effective causal therapy for preventing paclitaxel-induced peripheral neuropathy by suppression of Schwann cell dedifferentiation.
Koyanagi M; Imai S; Iwamitsu Y; Matsumoto M; Saigo M; Moriya A; Ogihara T; Nakazato Y; Yonezawa A; Nakagawa S; Nakagawa T; Matsubara K
Neuropharmacology; 2021 May; 188():108514. PubMed ID: 33684416
[TBL] [Abstract][Full Text] [Related]
16. Differential resistance to platinum-based drugs and 5-fluorouracil in p22phox-overexpressing oral squamous cell carcinoma: Implications of alternative treatment strategies.
Hung CC; Chien CY; Chu PY; Wu YJ; Lin CS; Huang CJ; Chan LP; Wang YY; Yuan SF; Hour TC; Chen JY
Head Neck; 2017 Aug; 39(8):1621-1630. PubMed ID: 28498554
[TBL] [Abstract][Full Text] [Related]
17. Association between Genetic Variants and Peripheral Neuropathy in Patients with NSCLC Treated with First-Line Platinum-Based Therapy.
de Jong C; Herder GJM; van Haarlem SWA; van der Meer FS; van Lindert ASR; Ten Heuvel A; Brouwer J; Egberts TCG; Deneer VHM
Genes (Basel); 2023 Jan; 14(1):. PubMed ID: 36672910
[TBL] [Abstract][Full Text] [Related]
18. Ototoxicity and Platinum Uptake Following Cyclic Administration of Platinum-Based Chemotherapeutic Agents.
Gersten BK; Fitzgerald TS; Fernandez KA; Cunningham LL
J Assoc Res Otolaryngol; 2020 Aug; 21(4):303-321. PubMed ID: 32583132
[TBL] [Abstract][Full Text] [Related]
19. Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.
Jimeno A; Machiels JP; Wirth L; Specenier P; Seiwert TY; Mardjuadi F; Wang X; Kapp AV; Royer-Joo S; Penuel E; McCall B; Pirzkall A; Clement PM
Cancer; 2016 Dec; 122(24):3803-3811. PubMed ID: 27525588
[TBL] [Abstract][Full Text] [Related]
20. Platinum compounds in the treatment of advanced breast cancer.
Martín M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
